MET and non-small cell lung carcinoma: Crizotinib is a small-molecule oral selective inhibitor of anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor (HGF) receptor, and ROS1 receptor kinase, which has been approved by the Food and Drug Administration (FDA) for the treatment of ALK rearrangement that is positive with metastatic non-small-cell lung cancer (NSCLC) [27].